Raiffeisen Bank International AG Buys Shares of 4,995 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Raiffeisen Bank International AG purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel reports. The fund purchased 4,995 shares of the biopharmaceutical company’s stock, valued at approximately $3,510,000.

Other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating for the company in a research report on Wednesday, April 30th. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $890.60.

Regeneron Pharmaceuticals Stock Up 2.4%

REGN opened at $584.99 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20. The stock’s fifty day simple moving average is $602.44 and its 200 day simple moving average is $686.93. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market cap of $63.95 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the company earned $9.55 earnings per share. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.